Showing posts with label protectionism. Show all posts
Showing posts with label protectionism. Show all posts

Thursday, May 5, 2011

UNAIDS Now Open About Being Pharmaceutical Industry Mouthpiece

The English Guardian has suddenly noticed that "Beating copyright infringement in the third world could be as simple as making products affordable". I have argued this on several occasions in the last few years, including here and here, but I would not be the first person to make this point.

However, I'm happy to hear that Joe Karaganis and others have spent three years researching the issue and come up with the Media Piracy in Emerging Economies report. But I don't expect that to make much difference to the position of people in developing countries.

It is also worth stressing that intellectual property (IP) protection, one of the most popular forms of trade protection among those who ostensibly oppose trade protection, is not paid for by those who benefit from it; it is paid for by consumers, in rich and poor countries alike. It's like a kind of tax that we pay to protect the interests of the rich. And it can represent well over 90% of the revenue that IP owners receive.

The report is also important in being independent, unlike much of what we read about IP, copyright issues, piracy, counterfeiting, fakes and whatever else industry is currently whining about.

We might think that everyone can do without luxury goods, especially people who are also short of water, food and medicine. However, various multinationals are doing everything in their power to control water, somehow or other, they already control food to a large extent and the drug industry is almost entirely run on profits inflated by IP protection.

There may be a lot of talk from Bill Clinton, Bill Gates, the World Trade Organization (WTO), UNAIDS and others about generic medicines and making drugs affordable. But prices of vital drugs are also protected by the same means as other goods. Even drugs whose cost has 'dropped' from the astronomical thousands of dollars per year to not much more than 100 dollars, are protected. The ultimate price charged is 100% controlled by the rich and powerful.

Therefore, the 'South African Generic Medicines Association' may sound touchy-feely enough, what with the 'African' and the 'generic' bits. But it is as much part of the pharmaceutical industry as AVAC or any of these other front groups that claim to be trying to keep costs down and make pharmaceutical products more accessible.

A speech by Paul de Lay of UNAIDS makes it clear who his intended audience is and who stands to benefit from any agreements that are made when it comes to generic drug pricing. The prices discussed may seem affordable when compared to the ridiculous prices they are replacing. But in reality, they are only affordable to the aid industry, not to the people who need them.

And the aid money going towards overpriced generic drugs is effectively another subsidy for those who ostensibly despise subsidies. This is money that could be better spent on the care people need, beyond the mere distribution of drugs, nurses, doctors, other health personnel and much else. But it is not the needs of HIV positive people that are being served here.

Incidentally, de Lay's speech mentions what he considers to be three areas of discussion, HIV prevention, treatment and health delivery. In reality, all three of these refer to drugs, to be paid for by aid money. To date, a relatively small percentage of HIV spending has gone towards prevention, but the industry has agreed that putting more people, HIV positive and negative, on drugs will prevent HIV transmission. And health delivery may sound like more than drugs, but it isn't really. Just read the speech.

It's wonderful how the interests of UNAIDS and the HIV industry as a whole now matches the interests of the global pharmaceutical industry. In fact, UNAIDS' HIV strategy can be summed up in one word: drugs. You can waste a lot more words on it, and you can be sure that UNAIDS and others will, but in the end, drugs are it.

De Lay advocates TRIPS (Trade Related Intellectual Property Rights), TRIPS Plus, Economic Partnership Agreements (EPA) and all sorts of other institutions and instruments that only point to one thing: intellectual property and the protection of the very rich against the very needy. The consortium of partners includes the wHO, the World Bank, the Gates Foundation (financed by IP protection) and a few others.

So it's official: the entire HIV industry, fronted by UNAIDS, is run by and for big pharma, and much of the aid industry will continue to subsidise and represent the interests of other industry sectors. The whole pretense of humanitarian motives can now be abandoned, as no one was fooled anyway. But, more worryingly, few seem to object to this either.

allvoices

Monday, April 11, 2011

'Counterfeiting' is a Problem That Can Only Be Solved By Big Pharma

If a business produces something and sells it for a price that covers costs and also gives a decent profit, that's a good model. Others may make the same thing, so a business needs to make the best and work hard to make sure they are not undercut. But most people will pay for something good rather than something that isn't up to scratch, if they can afford it.

However, if a business produces something and sells it for a price that is a complete distortion of the above business model, it is worthwhile for someone else to produce the same thing and charge a lot less. They don't even have to cut costs, they can just accept a lower profit. And those who have no chance of affording the expensive product may well be able to afford the cheaper one.

This is an oversimplification, but it is roughly what the pharmaceutical industry does, charges an outrageous price for something because they can. In addition, the industry depends on a form of protectionism called 'intellectual property rights'. Arguably, this has its uses, even that it is vital, but it is still a form of protectionism.

Often, the research that pharmaceutical companies claim to spend so much on is done by publicly funded, or partially publically funded, institutions. But there is little or no return to the public. And the amount spent on PR and marketing far exceeds what is actually spent on research.

So when someone else makes the same product but demands less for it, the industry reacts by resorting to all sorts of tricks to make sure the competition is destroyed. Competition, when you don't have a high level of trade protection, is not appreciated by the pharmaceutical industry.

The word 'counterfeit', therefore, can mean all sorts of things. It can mean a generic version of a branded drug, a fake version of a branded drug, a substandard version of a branded drug and probably other things. But a generic version of a branded drug is not a counterfeit and claiming that it is one threatens to deny  lifesaving treatments to many people in developing countries.

If drug companies don't want generic versions of their drugs to be produced, they should produce affordable versions themselves. There is clearly a huge market for them and a very good profit to be made. Dropping the price to affordable levels would also make the production of substandard and fake drugs a lot less tempting, perhaps not even worth the effort.

But instead of encouraging the production of generic drugs, the EU and, of course, the entire pharmaceutical industry, want to make sure affordable versions of drugs are not produced. They are currently trying to rope India into signing a 'trade agreement' whereby it will no longer be possible for the country to produce cheap drugs. Yet another form of protectionism.

India is one of the main sources of affordable drugs for developing countries. Some drugs will cost many times, perhaps even tens or hundreds of times more, just because they are protected by the sort of regulation that big industry claims to detest.

There is no doubt that some drugs are fake, made of materials that have no effect or are harmless, and this is unacceptable. But as long as ridiculous profits are made from drug pricing models, people will always find ways of selling their versions, no matter how useless or dangerous. It's not as if copyrighted drugs are always effective, or that they are never dangerous, either.

The pharmaceutical industry, already protected and subsidised in so many ways, wants more public money to be used to 'regulate' drug supplies in developing countries. Multinationals refuse regulation for themselves, but they seem to love the idea of regulating any competition.

Big Pharma have effectively created counterfeiting and many other related problems themselves, it's how they keep their profits so inordnately high. So they should sort it out themselves. If people object to the danger to the health and lives of so many people, they should aim their objections at the industry, the problem, not the mere symptoms of the problem.

The Science and Development Network have a selection of articles on the subject of 'counterfeit' drugs and some of the many issues involved. But the article doesn't really point out that Big Pharma don't lose out from counterfeiting because most of those who buy cheap drugs will never be able to afford the expensive versions.

allvoices

Thursday, June 17, 2010

Fake Aid to be Cut: Recipients May Benefit

It isn't often that government departments admit that they got something wrong but it's no less welcome when they do. The two Kenyan departments responsible for health (two because of the power sharing government) agree that they were wrong to pass the anti-counterfeiting bill in a form that failed to distinguish between counterfeit and fake. They accept that this could lead to people being unable to purchase affordable versions of vital drugs, including HIV drugs. India was particularly worried as they supply most of the generic drugs that Kenya and other African countries purchase.

The Kenyan health departments claim that the law in question was pushed by the Ministry for Industry, who didn't realise the implications of the wording of the law. Both these claims sound suspect and the whole issue of a bill which was so stacked in favour of the pharmaceutical industry and against the generic drug industry smelled of industry lobbying and arm twisting. And in practice, even without this law, enormous amounts of money are spent on non-generic, branded products, despite the availability of generics that cost a fraction of the brand price.

Most money spent on health in Sub-Saharan African countries comes from donors. This is one of the reasons that unnecessary amounts of money are spent on overpriced branded drugs. African countries certainly couldn't have afforded them. Some even suspect that a lot of foreign donor money is specifically made available for branded drugs in order to destroy the generic market. After all, branding, intellectual property, is a particularly egregious form of market protection. And there are few who like to protect their markets more than the pharmaceutical industry, regardless of how many people suffer or die from treatable and preventable illnesses as a result.

But this is not the end of the matter. The European Union, that bastion of free market talk and protectionist action, wants India to sign up to a 'Free Trade' Agreement which will effectively restrict the country's ability to produce generics and sell them to poor countries. Médecins Sans Frontières (MSF) is campaigning against this appalling threat to the health and lives of so many people, but most international health institutions are remaining silent.

Many other African countries followed Kenya's unwise decision to pass intellectual property law that only benefited pharmaceutical multinationals, so maybe some of them will reconsider this now. Perhaps they will also get behind MSF and any other organisations involved in campaigning for fair economic conditions for developing countries. Tanzania and others are wondering how they will fare now that so much donor funding has been cut, with the global economic crisis being used as an excuse. They will do a lot better when they exercise their right to purchase generic drugs, rather than wasting the ample HIV funding on extortionately priced brands.

Multinationals and other pushers are constantly bleating about how people in developing are suffering and all rich country governments need to do is pay for their products for things to be ok. But there just isn't enough money to buy branded products, nor is there any necessity to do so. Much of the current HIV transmission in developing countries is preventable, especially transmission from mother to child. But despite the relevant drugs being available for many years, an estimated 43,000 babies were infected by their mothers in Tanzania in 2008 alone. Of the 217,704 new infections, many more would have been the result of lack of proper equipment for ensuring proper levels of medical safety. Tanzania need to find affordable drugs and medical equipment so that they can get by with less money.

The issue of intellectual property protectionism goes far beyond essential drugs and medications. Most household product markets in Kenya and other African countries are dominated by one single brand or a handful of brands, for example, soap, sanitary pads, diapers, cleaning materials, etc. These brands are unnecessarily expensive but one disinfectant soap manufacturer even claims that using their soap makes you and your children 100% healthier. Such claims, leading people to believe that they are harming their families if they don't use these products, are widely advertised. That is where much of the money made by multinationals is spent; it's spent on marketing and advertising, not on research, as they would like us to believe.

Let multinationals do their own dirty work, they should not be entitled to donor money that is supposed to be spent on needy people. If these organisations are bothered by competition from generics, let them put their prices down and learn how to compete, for a change. They love talking about competition but they usually operate in completely protected environments. And if they think those producing fakes are worth fighting, they could just lower their prices enough so that it is no longer worth while producing fakes. Fakes are only economic when the cost of making the goods is low but the price charged is high. Multinationals should start abiding by some of the principles they seem to think are so important. They have priced themselves out of the market that they have worked so hard to rig in their favour.

Countries like Kenya and Tanzania are right to be worried about reduced funding but there are two things that may work in their favour. Firstly, if they are less dependent on donor funding, they may be better able to shop around for affordable drugs and other vital goods. At present, donors usually decide which drugs and goods to purchase and they favour their own markets. That's what being a donor is all about, isn't it! Secondly, they may find ways of achieving even more with less money once they are freed of all the restrictions that foreign loans and donations often carry. This is not an argument for reducing funding, which I think should be increased. But it is an argument for funding to become more transparent, more democratic, more like genuine funding than merely a tool for benefiting the donor far more than the recipient, as it appears now.

allvoices